Fig. 2

Expression of LincIN in clinical samples. a LincIN expression was evaluated by RNAcope^® ISH analysis on FFPE tissue microarrays (TMA) containing normal breast tissue and invasive breast carcinoma. To exclude low-quality tissue specimens due to potential RNA degradation, we simultaneously performed RNAScope^® ISH experiments in positive (POLR2) and negative (dapB) controls in serial TMA sections. b Analysis of RNA-ISH scores in 88 tumor and 31 normal samples using the two-sample Wilcoxon test. c Analysis of RNA ISH scores in 27 tumor and normal paired samples using the two-sample Wilcoxon test. d LincIN RNAseq expression data (RPKM value) for 88 normal-tumor pairs were retrieved from TCGA. The Wilcoxon signed-rank test was used for the comparison of matched pairs. e Overall survival (OS) from initial pathologic diagnosis was estimated using Kaplan-Meier methods, based on vital status and “days to death” or “days to last follow-up”. Individuals who were still alive at the time of last the follow-up were censored